COST BENEFIT ANALYSIS OF INTRAVENOUS (IV) TO ORAL (PO) SWITCH OF PARACETAMOL IN A TERTIARY CARE HOSPITAL
Senior Clinical Pharmacist, Dept. of pharmacy, Shaukat Khanum Memorial Cancer Hospital & Research Center Associate Director Pharmaceutical & Ambulatory Care Services, Dept. of pharmacy, Shaukat Khanum Memorial Cancer Hospital & Research Center. Resident Pharmacist, Dept. of pharmacy, Shaukat Khanum Memorial Cancer Hospital & Research Center. Staff Pharmacist, Dept. of pharmacy, Shaukat Khanum Memorial Cancer Hospital & Research Center
Keywords: Intravenous, Oral, Paracetamol
Abstract

Background: Intravenous to oral switch of medication in clinically stable patients is a part of appropriate medication reconciliation process, which ensures lower cost and reduced hospital stay. Paracetamol injection use has been very frequent in hospital setting especially during emergency care.At Shaukat Khanum Memorial Cancer Hospital 7 Research Center (SKMCH&RC), an online restriction for paracetamol injection prescribing was introduced in Jun, 2014 to ensure parenteral use only in indicated cases. Aim: In this retrospective study, it was intended to evaluate the impact of online IV paracetamol restriction on consumption of parenteral paracetamol in the institute. Method:It was a retrospective cross-sectional study. Paracetamol injection consumption was observed for the year 2014 month-wise using hospital information system (HIS). Results:The number of paracetamol injections used before implementation of restriction was 11429 from Jan to Jun, 2014. After implementation of restriction, the number was reduced to 8219 in total from Jun, 2014 to Dec, 2014. There was a 28.1% decrease in the use of paracetamol injectable dosage form after implementation of the restriction. Rs. 321,000/- approx. were saved as a result of reduced consumption. Conclusion: Restriction of intravenous paracetamol prescribing is associated with reduced parenteral paracetamol prescribing and lower cost of therapy.

Article Information

Identifiers and Pagination:
Year:2015
Volume:7
First Page:92
Last Page:97
Publisher Id:19204159.7:2.2015
Article History:
Received:January 2, 2015
Accepted:March 3, 2015
Collection year:2015
First Published:April 1, 2015


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
doi: http://dx.doi.org/10.21065/19204159
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/